ANAB

Company Overview — What Does ANAPTYSBIO, INC Do?

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. ANAPTYSBIO, INC (ANAB) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Daniel R. Faga and employs approximately 100 people. With a market capitalization of $1.6B, ANAB is one of the notable companies in the Healthcare sector.

ANAPTYSBIO, INC (ANAB) Stock Rating — Hold (April 2026)

As of April 2026, ANAPTYSBIO, INC receives a Hold rating with a composite score of 40.7/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ANAB ranks #911 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ANAPTYSBIO, INC ranks #65 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ANAB Stock Price and 52-Week Range

ANAPTYSBIO, INC (ANAB) currently trades at $70.10. The stock gained $1.56 (2.3%) in the most recent trading session. The 52-week high for ANAB is $68.39, which means the stock is currently trading 2.5% from its annual peak. The 52-week low is $15.40, putting the stock 355.2% above its annual trough. Recent trading volume was 460K shares, suggesting relatively thin trading activity.

Is ANAB Overvalued or Undervalued? — Valuation Analysis

ANAPTYSBIO, INC (ANAB) carries a value factor score of 48/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 118.13x, compared to the Healthcare sector average of 23.63x — a premium of 400%. The price-to-book ratio stands at 48.00x, versus the sector average of 2.75x. The price-to-sales ratio is 11.42x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ANAB trades at 9.32x EV/EBITDA, versus 6.34x for the sector.

Overall, ANAB's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

ANAPTYSBIO, INC Profitability — ROE, Margins, and Quality Score

ANAPTYSBIO, INC (ANAB) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -257.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -26.3% versus the sector average of -33.1%.

The operating margin is -61.8% (sector: -66.1%). Net profit margin stands at -101.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 595.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ANAB Debt, Balance Sheet, and Financial Health

ANAPTYSBIO, INC has a debt-to-equity ratio of 879.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 9.07x, indicating strong short-term liquidity. Cash and equivalents stand at $110M.

ANAB has a beta of 0.80, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for ANAPTYSBIO, INC is 49/100, reflecting average volatility within the normal range for its sector.

ANAPTYSBIO, INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, ANAPTYSBIO, INC reported revenue of $156M and earnings per share (EPS) of $-0.46. Net income for the quarter was $-96M. Operating income came in at $-42M.

In FY 2025, ANAPTYSBIO, INC reported revenue of $235M and earnings per share (EPS) of $-0.46. Net income for the quarter was $-13M. Revenue grew 157.0% year-over-year compared to FY 2024. Operating income came in at $48M.

In Q3 2025, ANAPTYSBIO, INC reported revenue of $76M and earnings per share (EPS) of $0.54. Net income for the quarter was $15M. Revenue grew 154.3% year-over-year compared to Q3 2024. Operating income came in at $35M.

In Q2 2025, ANAPTYSBIO, INC reported revenue of $22M and earnings per share (EPS) of $-1.34. Net income for the quarter was $-39M. Revenue grew 102.9% year-over-year compared to Q2 2024. Operating income came in at $-26M.

Over the past 8 quarters, ANAPTYSBIO, INC has demonstrated a growth trajectory, with revenue expanding from $11M to $156M. Investors analyzing ANAB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ANAB Dividend Yield and Income Analysis

ANAPTYSBIO, INC (ANAB) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ANAB Momentum and Technical Analysis Profile

ANAPTYSBIO, INC (ANAB) has a momentum factor score of 74/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 20/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 5/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ANAB vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ANAPTYSBIO, INC (ANAB) ranks #65 out of 838 stocks based on the Blank Capital composite score. This places ANAB in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ANAB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ANAB vs S&P 500 (SPY) comparison to assess how ANAPTYSBIO, INC stacks up against the broader market across all factor dimensions.

ANAB Next Earnings Date

No upcoming earnings date has been announced for ANAPTYSBIO, INC (ANAB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ANAB? — Investment Thesis Summary

ANAPTYSBIO, INC presents a balanced picture with arguments on both sides. The quality score of 25/100 flags below-average profitability. Price momentum is positive at 74/100, suggesting the trend favors buyers.

In summary, ANAPTYSBIO, INC (ANAB) earns a Hold rating with a composite score of 40.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ANAB stock.

Related Resources for ANAB Investors

Explore more research and tools: ANAB vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ANAB head-to-head with peers: ANAB vs AZN, ANAB vs SLGL, ANAB vs VMD.